Role of anticoagulation in lowering the mortality in hospitalized covid-19 patients

References

1. 1.↵
   World Health Organization. COVID-19 Dashboard. [Updated 2021; cited 2021 September 6]. Available from: https://covid19.who.int/
2. 2.↵
   1. Porfidia A,
   2. Valeriani E,
   3. Pola R,
   4. Porreca E,
   5. Rutjes A,
   6. Di Nisio M.

   Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thrombosis Research 2020; 196: 67–74.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Motta J,
   2. Ogunnaike R,
   3. Shah R,
   4. Stroever S,
   5. Cedeño H,
   6. Thapa S, et al.

   Clinical outcomes with the use of prophylactic versus therapeutic anticoagulation in coronavirus disease 2019. Crit Care Explor 2020; 2: e0309.

   OpenUrlPubMed
4. 4.↵
   1. Loo J,
   2. Spittle D,
   3. Newnham M.

   COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax 2021; 76: 412–420.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Iba T,
   2. Levy J,
   3. Levi M,
   4. Thachil J.

   Coagulopathy in COVID-19. J Thromb Haemost 2020; 18: 2103–2109.

   OpenUrlPubMed
6. 6.↵
   1. Musoke N,
   2. Lo K,
   3. Albano J,
   4. Peterson E,
   5. Bhargav R,
   6. Gul F, et al.

   Anticoagulation and bleeding risk in patients with COVID-19. Thromb Res 2020; 196: 227–230.

   OpenUrlCrossRefPubMed
7. 7.
   1. Tang N,
   2. Bai H,
   3. Chen X,
   4. Gong J,
   5. Li D,
   6. Sun Z.

   Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Thromb Res 2020; 18: 1094–1099.

   OpenUrl
8. 8.↵
   1. Ionescu F,
   2. Grasso-Knight G,
   3. Castillo E,
   4. Naeem E,
   5. Petrescu I,
   6. Imam Z, et al.

   Therapeutic anticoagulation delays death in COVID-19 patients: Cross-sectional analysis of a prospective cohort. TH Open 2020; 4: e263–e270.

   OpenUrl
9. 9.↵
   1. Lu YF,
   2. Pan LY,
   3. Zhang WW,
   4. Cheng F,
   5. Hu SS,
   6. Zhang X, et al.

   A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. Int J Infect Dis 2020; 100: 34–41.

   OpenUrlCrossRef
10. 10.↵
    1. Begbie M,
    2. Notley C,
    3. Tinlin S,
    4. Sawyer L,
    5. Lillicrap D

    (2000) The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP. Thromb Haemost 84: 216–222.

    OpenUrlPubMed
11. 11.↵
    1. SJ Zost,
    2. Gilchuk P,
    3. Case JB,
    4. Binshtein E,
    5. Chen RE,
    6. Nkolola JP, et al.

    Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 2020; 584: 443–449.

    OpenUrl
12. 12.↵
    1. Han H,
    2. Ma Q,
    3. Li C,
    4. Liu R,
    5. Zhao L,
    6. Wang W,
    7. Zhang P, et al.

    Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect 2020; 9: 1123–1130.

    OpenUrl
13. 13.
    1. McGonagle D,
    2. Sharif K,
    3. O’Regan A,
    4. Bridgewood C.

    The Role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020; 19: 102537.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Wan S,
    2. Yi Q,
    3. Fan S,
    4. LV J,
    5. Zhang X,
    6. Guo L, et al.

    Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol 2020; 189: 428–437.

    OpenUrlCrossRef
15. 15.↵
    1. de Jonge E,
    2. Friederich PW,
    3. Vlasuk GP,
    4. Rote WE,
    5. Vroom MB,
    6. Levi M, et al.

    Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. Clin Diagn Lab Immunol 2003; 10: 495–497.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Mutlu GM,
    2. Green D,
    3. Bellmeyer A,
    4. Baker CM,
    5. Burgess Z,
    6. Rajamannan N, et al.

    Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway. J Clin Invest 2007; 117: 2952–2961.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Tomaske M,
    2. Candinas R,
    3. Weiss M,
    4. Bauersfeld U.

    Safety and efficacy of pediatric outpatient radio frequency catheter ablations. Int J Cardiol 2011; 148: 276–279

    OpenUrlPubMed
18. 18.↵
    1. Schmitt FCF,
    2. Manolov V,
    3. Morgenstern J,
    4. Fleming T,
    5. Heitmeier S,
    6. Uhle F, et al.

    Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care 2019; 9: 19.

    OpenUrl
19. 19.↵
    1. Di Minno A,
    2. Ambrosino P,
    3. Calcaterra I,
    4. Di Minno MND.

    COVID-19 and Venous thromboembolism: A meta-analysis of literature studies. Semin Thromb Hemost 2020; 46: 763–771.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Al-Samkari H,
    2. Karp Leaf RS,
    3. Dzik WH,
    4. Carlson JCT,
    5. Fogerty AE,
    6. Waheed A, et al.

    COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020; 136: 489–500.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Mai V,
    2. Tan BK,
    3. Mainbourg S,
    4. Potus F,
    5. Cucherat M,
    6. Lega JC, et al.

    Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis. Vascul Pharmacol 2021; 139: 106882.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Lawler PR,
    2. Goligher EC,
    3. Berger JS, et al.

    ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, et al. Therapeutic anticoagulation with heparin in noncritically Ill patients with Covid-19. N Engl J Med 2021; 385: 790–802.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Goligher EC,
    2. Bradbury CA,
    3. McVerry BJ, et al.

    REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19. N Engl J Med 2021; 385: 777–789.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Klok FA,
    2. Kruip MJHA,
    3. van der Meer NJM,
    4. Arbous MS,
    5. Gommers DAMPJ,
    6. Kant KM, et al.

    Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145–147.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Russo V,
    2. Di Maio M,
    3. Attena E,
    4. Silverio A,
    5. Scudiero F,
    6. Celentani D, et al.

    Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. Pharmacol Res 2020; 159: 104965.

    OpenUrlPubMed
26. 26.↵
    1. Tremblay D,
    2. van Gerwen M,
    3. Alsen M,
    4. Thibaud S,
    5. Kessler A,
    6. Venugopal S, et al.

    Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. Blood 2020; 136: 144–147.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Kollias A,
    2. Kyriakoulis KG,
    3. Lagou S,
    4. Kontopantelis E,
    5. Stergiou GS,
    6. Syrigos K.

    Venous thromboembolism in COVID-19: A systematic review and meta-analysis. Vasc Med 2021; 26: 415–425.

    OpenUrl
28. 28.
    1. Hasan SS,
    2. Radford S,
    3. Kow CS,
    4. Zaidi STR.

    Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. J Thromb Thrombolysis 2020; 50: 814–821.

    OpenUrlCrossRef
29. 29.↵
    1. Tassiopoulos AK,
    2. Mofakham S,
    3. Rubano JA,
    4. Labropoulos N,
    5. Bannazadeh M,
    6. Drakos P, et al.

    D-dimer-driven anticoagulation reduces mortality in intubated COVID-19 patients: A cohort study with a propensity-matched analysis. Front Med (Lausanne) 2021; 8: 631335.

    OpenUrl
30. 30.
    1. Paolisso P,
    2. Bergamaschi L,
    3. D’Angelo EC,
    4. Donati F,
    5. Giannella M,
    6. Tedeschi S, et al.

    Preliminary experience with low molecular weight heparin strategy in COVID-19 patients. Front Pharmacol 2020; 11: 1124.

    OpenUrlCrossRefPubMed
31. 31.
    1. Lemos ACB

    , do Espírito Santo DA, Salvetti MC, Gilio RN, Agra LB, Pazin-Filho A, Miranda CH. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb Res 2020; 196: 359–366.

    OpenUrlCrossRefPubMed
32. 32.
    1. Helms J,
    2. Severac F,
    3. Merdji H,
    4. Schenck M,
    5. Clere-Jehl R,
    6. Baldacini M, et al.

    Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study. Ann Intensive Care 2021; 11: 14.

    OpenUrlPubMed
33. 33.
    1. Zhu W,
    2. Zhang H,
    3. Li Y,
    4. Ding Z,
    5. Liu Z,
    6. Ruan Y, et al.

    Optimizing management to reduce the mortality of COVID-19: experience from a designated hospital for severely and critically Ill patients in China. Front Med (Lausanne) 2021; 8: 582764.

    OpenUrl
34. 34.
    1. Yu B,
    2. Gutierrez VP,
    3. Carlos A,
    4. Hoge G,
    5. Pillai A,
    6. Kelly JD, et al.

    Empiric use of anticoagulation in hospitalized patients with COVID-19: a propensity score-matched study of risks and benefits. Biomark Res 2021; 9: 29.

    OpenUrl
35. 35.
    1. Poulakou G,
    2. Dimakakos E,
    3. Kollias A,
    4. Kyriakoulis KG,
    5. Rapti V,
    6. Trontzas I, et al.

    Beneficial effects of intermediate dosage of anticoagulation treatment on the prognosis of hospitalized COVID-19 patients: The ETHRA Study. In Vivo 2021; 35: 653–661.

    OpenUrlAbstract/FREE Full Text
36. 36.
    1. Sadeghipour P,
    2. Talasaz AH,
    3. Rashidi F,
    4. Sharif-Kashani B,
    5. Beigmohammadi MT,
    6. Farrokhpour M, et al.

    Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION randomized clinical trial. JAMA 2021; 325: 1620–1630.

    OpenUrlCrossRefPubMed
37. 37.
    1. Meizlish ML,
    2. Goshua G,
    3. Liu Y,
    4. Fine R,
    5. Amin K,
    6. Chang E, et al.

    Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. Am J Hematol 2021; 96: 471–479.

    OpenUrlCrossRefPubMed
38. 38.
    1. Goligher EC,
    2. Bradbury CA,
    3. McVerry BJ,
    4. Lawler PR,
    5. Berger JS,
    6. Gong MN, et al.

    Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19. N Engl J Med 2021; 385: 777–789.

    OpenUrlCrossRefPubMed
39. 39.
    1. Atalla E,
    2. Zhang R,
    3. Shehadeh F,
    4. Mylona EK,
    5. Tsikala-Vafea M,
    6. Kalagara S, et al.

    Clinical presentation, course, and risk factors associated with mortality in a severe outbreak of COVID-19 in Rhode Island, USA, April-June 2020. Pathogens 2020; 10: 8.

    OpenUrl
40. 40.
    1. Rentsch CT,
    2. Beckman JA,
    3. Tomlinson L,
    4. Gellad WF,
    5. Alcorn C,
    6. Kidwai-Khan F, et al.

    Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ 2021; 372: n311.

    OpenUrlAbstract/FREE Full Text